A Phase 1, Open-Label Study of ABSK112 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Non-Small Cell Lung Cancer
Latest Information Update: 20 Mar 2024
At a glance
- Drugs ABSK 112 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; First in man
- Sponsors Abbisko Therapeutics
Most Recent Events
- 17 Jan 2024 Status changed from not yet recruiting to recruiting.
- 07 Jul 2023 New trial record
- 04 Jul 2023 According to Abbisko Therapeutic media release, the company announced that IND has been approved by FDA for this phase I clinical trial.